Evidence map›Paper›PMID 23021099›Full record

Trial reportJournal of substance abuse treatment2013

Predictors of outcome after short-term stabilization with buprenorphine.

Maureen Hillhouse, Catherine P Canamar, Walter Ling

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of substance abuse treatment, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 3 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Buprenorphine for managing opioid withdrawal.The Cochrane database of systematic reviews · 2017
    Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Opioid agonist therapy.Canadian family physician Medecin de famille canadien · 2017
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Maureen HillhouseSemel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA 90025, USA. hillhous@ucla.edu
Catherine P Canamar
Walter Ling
University of California, Los Angeles · US

Funding

The National Drug Abuse Treatment Clinical Trials NetworkU10DA013045 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LING, WALTER NMN · 1999 to 2015
$52.6M
CU PARTNERS: NY/LONG ISLAND REGIONAL NODEU10DA013035 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI NUNES, EDWARD V., ROTROSEN, JOHN P · 2001 to 2015
$47.6M
CLINICAL TRIALS NETWORK: PACIFIC NORTHWEST NODEU10DA013714 · NIDA · UNIVERSITY OF WASHINGTON · PI DONOVAN, DENNIS MICHAEL, ROLL, JOHN M. · 2001 to 2015
$25.5M
CLINICAL TRIALS NETWORK MID-ATLANTIC COLLABORATIVE GROUPU10DA013034 · NIDA · JOHNS HOPKINS UNIVERSITY · PI SCHWARTZ, ROBERT P, STITZER, MAXINE L · 1999 to 2015
$25.2M
NIDA CLINICAL TRIALS NETWORK - NYC EAST SIDE NODEU10DA013046 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ROTROSEN, JOHN P · 2000 to 2009
$20.2M
OREGON NODE - NATIONAL CLINICAL TRIALS NETWORKU10DA013036 · NIDA · OREGON HEALTH & SCIENCE UNIVERSITY · PI MCCARTY, DENNIS · 1999 to 2010
$18.5M
CLINICAL TRIALS NETWORK: NEW ENGLAND NODEU10DA013038 · NIDA · YALE UNIVERSITY · PI CARROLL, KATHLEEN M. · 1999 to 2010
$17.3M
NATIONAL DRUG ABUSE TREATMENT CLINICAL TRIALS NETWORKU10DA013711 · NIDA · DUKE UNIVERSITY · PI HUBBARD, ROBERT L. · 2001 to 2008
$14.7M
ROCKY MOUNTAIN REGIONAL CLINICAL TRIALS NODEU10DA013716 · NIDA · UNIVERSITY OF COLORADO DENVER/HSC DENVER · PI RIGGS, PAULA DEGRAFFENREID · 2000 to 2005
$12.7M
NIDA NIH HHS U10 DA013034NIDA NIH HHS U10 DA013035NIDA NIH HHS U10DA 013035NIDA NIH HHS U10 DA 013036NIDA NIH HHS U10 DA013036NIDA NIH HHS U10 DA 013038NIDA NIH HHS U10 DA013038NIDA NIH HHS U10 DA013045NIDA NIH HHS U10 DA 013046NIDA NIH HHS U10 DA013046NIDA NIH HHS U10 DA013711NIDA NIH HHS U10 DA 013714NIDA NIH HHS U10 DA013714NIDA NIH HHS U10 DA013716NIDA NIH HHS U10DA13034NIDA NIH HHS U10DA13045NIDA NIH HHS U10DA13711NIDA NIH HHS U10DA13716
6 · The paper itself

Abstract

Using buprenorphine as a medication to treat opioid dependence is becoming more prevalent as illicit opiate use increases. Identifying the characteristics of opiate dependent individuals best suited to benefit from buprenorphine would improve guidelines for its administration. This study evaluates baseline and treatment participation variables for predicting positive response to short-term stabilization with buprenorphine. Data include demographic, drug use, and other variables collected from participants undergoing stabilization over a 4-week period before being tapered off buprenorphine in a short-term detoxification process. Outcome variables include opioid use and retention. Logistic regression results indicate several characteristics associated with opioid use at the end of the stabilization period. These include being older, having no criminal history, and less opiate use. Criminal activity and opioid use in the last 30 days were significantly associated with shorter treatment stays. The benefits of identifying individual characteristics that may predict treatment response are discussed.

Indexed as

Age FactorsBuprenorphineCrimeFemaleHumansLogistic ModelsMaleNarcotic AntagonistsOpiate Substitution TreatmentOpioid-Related DisordersPsychiatric Status Rating ScalesSubstance Withdrawal SyndromeTime FactorsTreatment OutcomeBuprenorphineNarcotic Antagonists

Identifiers

PMID23021099
PMCPMC3545105
OpenAlexW2030958819

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.